Education
About Us
Working with TipRanks
Follow Us
Cybin (TSE:CYBN)
NEO-L:CYBN
CYBN Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.14 - C$0.14
Previous CloseN/A
Volume13.54K
Average Volume (3M)0.00
Market Cap
$1.97M
Enterprise ValueN/A
Total Cash (Recent Filing)$136.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 17, 2025EPS Estimate
-1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,590,025
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$127.89Price Target Upside91252.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCYB003's 71% remission rate at 12 months following two 16 mg doses, coupled with its FDA Breakthrough Therapy Designation, underscore meaningful registration potential.
Financial FlexibilityThe recent announcement of a US$500 million convertible debenture facility—with US$50 million now funded—provides additional capital flexibility and extends runway beyond 2026.
Regulatory ProgressCYB003’s durability signal and Breakthrough Therapy Designation, combined with CYB004’s short-acting profile, position Cybin to deliver differentiated, intermittent treatments across mood and anxiety disorders.
Bears Say
Market ReactionThe trial achieved statistical significance on the primary endpoint, but CMPS stock reacted negatively and since this was a bellwether event for psychedelic stocks, the group, including Cybin, also traded down.
Valuation ConcernsCYBN still does not ascribe any value for CYB004 for generalized anxiety disorder in the valuation, viewing the product as not reflected in the stock in any appreciable way.
Cybin News
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was C$0.14 and its highest was C$0.14 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.97M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Nov 17, 2025 which is in 80 days.
How were Cybin’s earnings last quarter?
Currently, no data Available
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -1.33.
How many shares outstanding does Cybin have?
Cybin has 23,590,025 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in TSE:CYBN
Company Description
Cybin
Cybin (CYBN) is a biotechnology company focused on advancing psychedelic therapeutics for mental health disorders. Operating primarily in the pharmaceutical sector, Cybin is dedicated to the research and development of psychedelic compounds, aiming to improve patient outcomes through novel drug formulations and delivery systems. The company's core services include clinical trials, drug development, and partnerships with research institutions to explore the therapeutic potential of psychedelics.
CYBN Stock 12 Month Forecast
Average Price Target
C$127.89
▲(91252.32% Upside)
Technical Analysis
Restart Life Sciences
―
Waverley Pharma
―
MYND Life Sciences
―
―
Doseology Sciences
―
Ownership Overview
―
Insiders
―
Mutual Funds
26.34% Other Institutional Investors
72.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---